Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Harvest Connect Announces Investment by Multi-Hyphenate Tip “T.I.” Harris in its Most Recent Round of Funding in the Advancement of Georgia’s Medical Cannabis Industry


Harvest Connect

T.I. and his team have been fully aligned with our vision of helping Georgia farmers, Georgia patients, and Georgia under-served communities.

Harvest Connect LLC, a Georgia-based medical cannabis and retail company, announces its partnership with Tip “T.I.” Harris and his company, King of Da South, LCC, as an investor and equity partner. The Atlanta native is a prominent figure in the entertainment industry as a rapper, singer, actor, songwriter, producer, record executive, podcast host and author. In addition, T.I. focuses his business ventures on entrepreneurship, political activism, and charitable works.

“We are extremely excited and humbled to have a talent and leader like T.I. involved with Harvest Connect. T.I. and his team have been fully aligned with our vision of helping Georgia farmers, Georgia patients, and Georgia under-served communities,” says Harvest Connect CEO Kevin P. Quirk. “T.I and his team bring fresh ideas, new audiences, and a compelling energy to the conversation. We look forward to exploring further collaboration, especially those initiatives that are near and dear to T.I.’s heart.”

Harvest Connect investor, LeMont Bradley, introduced the idea to T.I. “After meeting with the team and hearing about their vision to focus on Georgians and under-served communities, I knew I wanted to be involved,” says T.I. “Together, I believe we can knock down barriers in the medical cannabis industry, and I’m looking forward to seeing what we can achieve.”

Harvest Connect is positioned well for gaining results for its current and future investment partners, as well as Georgia farmers, and Georgians who suffer from various ailments. The company has been successful with its early round funding preparing the way for the opening of its first retail location, a hemp processing facility, and a medical marijuana license once approved by the state.

“It is time to open this opportunity to more Georgia investors as we’ve been thoroughly preparing for the next phase of our operation,” continues Quirk. “We have a terrific base of existing business partners who continue to believe in our mission and have a deep-seated passion for helping people in all facets, especially those across the state living with chronic pain. It is an incredibly exciting and dynamic sector to be a part of right now.”

The Company’s retail store, CBD Store and More, is located in Historic Roswell on Canton Street and opened in April 2020. It carries the Harvest Connect brand of Graceleaf™ CBD products as well as other national brands. Through its partnership with T.I., the Company will white label certain product lines for the celebrity businessman currently under development and scheduled to launch in early 2021.

Harvest Connect and its family of brands, including CBD Store and More and Graceleaf, have assembled a team of Georgians who have been working in other states to build expertise across the entire supply chain for hemp-derived CBD and low-THC medical marijuana.

About Harvest Connect LLC

Harvest Connect LLC is a vertically integrated ingredient and brand company focused on Cannabis market from seed to sale. The Company manages the entire supply chain of CBD from the farms through the processing labs into our great consumer brands ultimately reaching directly to the consumer through company-owned retail locations, chain retailers and e-commerce. Harvest Connect’s brands include Graceleaf and CBD Store and More. Through its medical marijuana division, the Company addresses cultivation, processing, packaging and selling (retail and wholesale) of CBD, hemp and medical marijuana. To learn more, visit myharvestconnect.com and connect on LinkedIn for regular updates on the industry and company. For a prospectus and investment information, contact us at info@graceleaf.com.

About Tip “T.I.” Harris

Artist, Actor, Entrepreneur, Philanthropist, Podcast Host & Professor at Clark Atlanta University

Aside from his contributions in entertainment including, 11 hit albums, multiple Grammy’s, Billboard BET and American Music Awards, countless blockbuster movies and top-rated television shows including, ATL, VH-1’s T.I. & Tiny: The Family Hustle, American Gangster and Marvel’s Antman, to name a few, Tip “T.I.” Harris has made an indelible mark on the world of business. He is an artist, entrepreneur and activist who has amassed a business empire to include a record label, a 10-year-old clothing line (Akoo, which stands for “A King of Oneself”), a real estate holdings company, production company, non-profit organization (Us or Else), owner/founder of Trap Music Museum, co-owner of Bankhead Seafood, owner of Super Sound Studios, investor and much more. Harris served on the Mayor of Atlanta’s Transition Team, where he focused on policy and legislation; and currently serves on the Reimagining Atlanta Task Force, aimed at creating restorative practices and a community-driven approach to addressing incarceration. He has been recognized most recently as a thought leader at the United States Capitol and during the Operation Hope and Forbes Magazine business conferences. His community focus is around driving economic mobility and equity in vulnerable, underserved communities. Harris was also awarded the first-ever “Voice of the Culture” award by ASCAP and is the host of a new #1 rated podcast, expediTIously with Tip “T.I.” Harris.

Share article on social media or email:

ABSTRAX Announces New Wholesale Platform Offering the Most Extensive and Cost-Effective Catalogue of All-Natural Terpene Blends


Terpene Science

“We’ve officially recaptured our R&D costs and are now able to drastically reduce the cost of our products for both new and existing brands.”

ABSTRAX, a leader in the study and production of cannabis flavors, aromas and terpenes, is thrilled to share its all-new wholesale platform and custom formulation services with brands seeking to utilize science-backed terpene blends for vape, food, beverage, cosmetics, candles, and more.

“We’ve been servicing the biggest names in the industry for the last couple of years and working tirelessly on our research and development efforts to produce the very best terpene blends on the market today,” says Max Koby, Founding Partner and Chief Executive Officer of ABSTRAX. “We’ve officially recaptured our R&D costs and are now able to drastically reduce the cost of our products for both new and existing brands.”

ABSTRAX’s Natural Terpene Collection is the result of the company’s dedication to first-hand research done in its state-of-the-art type 7 licensed research and manufacturing lab where it’s award-winning product developers and scientists leverage the most advanced strain analysis technology to extract and study aroma compounds via three-dimensional analysis.

“No other terpene manufacturer studies terpenes to the degree that we do,” says Koby. “We are literally able to take a deep dive into each and every compound within every plant and cannabis strain we study. Our scientists and formulation team work magic with everything from leading cannabis strains to hemp, hops, fruits, coffee beans, and more to create unforgettable aromas, flavors, and sensorial experiences for consumers around the world.”

Leading brands and manufacturers including Sherbinskis, Wana Brands, Jack Herer and Goldenleaf Holdings turn to ABSTRAX for their terpene-related needs. “Our customers come to us because they know they’re getting the highest quality products and formulations based on pure science,” says Koby.

ABSTRAX’s Native Series is a perfect example of the innovation the company has achieved over the past couple of years. For the series, PhD scientists and product formulators have worked together to recreate some of the most revered and complex cannabis strains using botanically-derived, THC-free terpenes that can be shipped anywhere in the world. This effort includes the most in-depth analysis that has ever been done on cannabis strains in history — sometimes resulting in the identification of more than 400 terpenoids and aroma compounds and always resulting in formulations that smell and taste exactly the same and can be reproduced with unwavering consistency.

Beyond creating the most powerful terpene blends in the industry, the company goes the extra mile with companies of all sizes to provide custom formulation services and advanced cannabis testing services to reproduce terpene profiles for cannabis brands. And now, the company is doubling down on its commitment to reduce wholesale pricing by up to 30 percent, depending on scale.

“Beyond getting the best terpene blends on the market, our customers can rest easy because they are getting formulations that never include Diluents, PG (propylene glycol), VG (vegetable glycerin), or MCT oil. Plus, we’re TTB approved, organic compliant, NCIA compliant, FDA registered, FEMA GRAS and HACCP Certified, GMP compliant, ISO Certified, and Kosher,” says Koby.

For more information on wholesale pricing, custom formulations, and/or more information on the science of terpenes visit https://abstraxtech.com/pages/wholesale-benefits or call (562) 294-5805.

About ABSTRAX

Leveraging its proven background in cannabis research, ABSTRAX is the leader in the research, development, and production of botanically-derived and cannabis-inspired terpenes that create unforgettable sensorial experiences. Headquartered in California, the company owns and operates a state-of-the-art type 7 licensed research and manufacturing lab where it’s award-winning product developers and scientists leverage the most advanced strain analysis technology to extract and study aroma compounds via three-dimensional analysis, allowing for each and every compound within a plant to be named and studied. The company has partnered with many of the best cultivators in the industry to study their cannabis profiles and create the world’s most advanced terpene formulations. As a result of its efforts, ABSTRAX offers the largest terpene catalogue of the most popular strains – botanically-derived terpene blends and isolates native to cannabis. These ingredients, also known as functional flavors and aromas, are used in vapes, concentrates, edibles, beer, essential oils, fragrances, cosmetics, topicals, tinctures, alcohol, food and beverage, personal care, and more. The company works with internationally recognized brands and provides unparalleled cannabis research, innovation, and custom formulations to create products that engage and thrill consumers. ABSTRAX also devotes significant resources to developing the highest terpene standards and best practices in the industry. The company has developed a robust quality management system including Gas Chromatography analysis and molecular distillation of natural ingredients to achieve the highest purity standards. Investigating and ensuring that ingredients used in its own products, and products within its industry, are safe for consumption. The terpene industry is a rapidly growing segment of the global flavor and fragrance market, which is expected to grow to $35 billion by 2024. This market segment includes the cannabis, CBD, skincare, cosmetics, health and wellness, food and beverage industries. For more information, visit AbstraxTech.com.

Share article on social media or email:

Newport Beach Plastic Surgeon, Dr. Joseph Cruise, Explains His Tummy Tuck Belly Button Technique


“A belly button that is too big, stretched out, positioned too high or low, has no hooding, or displays a visible incision are tell-tale signs a person had tummy tuck surgery. My designer belly button ensures the most natural belly button result” – Dr. Cruise

The goal of most patients considering a tummy tuck is to improve issues such as loose skin, stubborn fat, and stretch marks. An abdominoplasty (tummy tuck) is a wonderful procedure for achieving a flat firmer abdomen and a more attractive body contour.

The key to a great result is ensuring the look is naturally beautiful, not operated on. This takes more than removing excess fat and skin, and tightening the abdominal muscles. The most overlooked part of a tummy tuck that can make or break the result is the belly button. Yes, the belly button!

The navel is the focal point of the abdomen and the first thing people see when your tummy is exposed. As such, the belly button must look natural so you can look and feel confident when wearing a bathing suit or clothing that exposes your midriff.

Achieving a natural looking belly button with tummy tuck surgery is one of the highest priorities for Newport Beach plastic surgeon Dr. Joseph Cruise. His designer belly button is coveted by patients who desire the best tummy tuck results available.

Top 4 Techniques for a Beautiful Belly Button

Create hooding so it is not an open round hole

Incision hidden inside

Trajectory facing slightly downward

Removable sutures to avoid track marks

Dr. Cruise uses these 4 superior techniques when “creating” the belly button during his tummy tuck procedures. The belly button is one of the focal points of a beautiful tummy tuck result. Understanding the importance of creating an attractive natural belly button is one factor that distinguishes the expertise of a plastic surgeon such as Dr. Cruise.

Generally speaking, the preferred look of a belly button is the “innie.” For Dr. Cruise, this means attention to detail when creating a natural depth within the belly button with a smooth hooding of skin and no visible incision. Dr. Cruise’s goal is to provide his patients with the most natural appearing belly button for their body so no one can detect they had tummy tuck surgery. This takes surgical precision not found with all plastic surgeons. There is a lot of finesse and skill that goes into creating a belly button that is aesthetically pleasing.

Dr. Cruise’s patients love their tummy tuck results, especially their attractive natural belly buttons! If you want to restore your mid-section with a tummy tuck and improve your confidence, contact Cruise Plastic Surgery today at 949-644-4808.

Share article on social media or email:

Slone Partners Places Phil Paik, Ph.D., as Vice President, Platform Development, at Molecular Assemblies


Molecular Assemblies

“Dr. Paik is an experienced industry leader who brings a track record of success over many years,” said Slone Partners President Tara Kochis-Stach.

Slone Partners, a nationwide executive search firm for life science, biotechnology, and diagnostics companies, has announced the placement of Phil Paik, Ph.D., as Vice President, Platform Development, at Molecular Assemblies, Inc. In his new role, Dr. Paik’s deep expertise in microfluidics and product development will be applied in advancing Molecular Assemblies’ breakthrough enzymatic DNA synthesis technology into a commercial platform.

Dr. Paik has more than 16 years of experience in technology innovation and platform development. Prior to joining Molecular Assemblies, he served as Associate Director of Engineering at Illumina, where he led the fluidics architecture development for both instrument and integrated cartridge-based platforms, and managed the fluidics engineering group within product development.

“Dr. Paik is an experienced industry leader who brings a track record of success over many years,” said Slone Partners President Tara Kochis-Stach. “His extensive knowledge and innovative foresight will be a wonderful addition to the strong Molecular Assemblies leadership team as the company moves into the next exciting phase of commercial development of its transformational enzymatic DNA synthesis technology.”

“We are excited to welcome Phil to Molecular Assemblies, where he will lead the development of our commercial enzymatic DNA synthesis platform,” said Michael J. Kamdar, President and CEO of Molecular Assemblies. “Phil’s deep expertise and experience in advancing microfluidic solutions to transform novel technologies into robust, commercial products will be invaluable as we empower enzymatic DNA synthesis to deliver rapid innovation for a broad range of industries, including synthetic biology, therapeutics, vaccines, agriculture, and DNA data storage.”

“I’m impressed by the enormous potential of enzymatic DNA synthesis to transform industries with the reliable, affordable, and sustainable production of long, high-quality DNA, at scale,” said Dr. Paik. “Molecular Assemblies not only has a proprietary technology position but also has an amazing team, dedicated partnerships, and supportive investors that propel the company to a leadership position in the field of enzymatic DNA synthesis.”

Dr. Paik began his career as a founding member of Advanced Liquid Logic, where he was responsible for the development of key functionalities and manufacturability of a novel digital microfluidic platform for lab-on-a-chip applications. He also served as senior microfluidics design engineer at ICx Technologies (acquired by FLIR Systems) under a division focused on the platform integration of high-performance assays for biodefense applications.

ABOUT SLONE PARTNERS

Slone Partners delivers the leaders who build amazing and diverse life sciences organizations – People Are Our Science®. Founded in 2000, Slone Partners specializes in delivering world-class C-suite leadership, executive, and upper management talent to the most promising and established biotech, diagnostics, research tools, healthcare, precision medicine, CRO, and laboratory services companies. With coast-to-coast presence in the most active healthcare industry hubs of Boston, San Francisco, New York, Los Angeles, San Diego, Austin, Research Triangle Park NC, and Washington DC, Slone Partners uniquely and precisely provides an array of executive search and advisory services, including diversity, equity, and inclusion strategy, to innovative life sciences companies. To learn more about Slone Partners’ value proposition and processes, visit http://www.slonepartners.com or call 888.784.3422.

ABOUT MOLECULAR ASSEMBLIES

Molecular Assemblies, Inc. is a private biotech company developing an enzymatic DNA synthesis technology designed to power the next generation of DNA-based products. The company’s patented enzymatic method, based on making DNA the way nature makes DNA, produces long, high-quality, sequence-specific DNA reliably, affordably, and sustainably. Molecular Assemblies’ technology will enable the reading and writing of DNA for industries including industrial synthetic biology and precision medicine, as well as emerging applications of DNA for data information storage, nanomachines, and bio-based electronics. Molecular Assemblies is headquartered in San Diego. For more information, please visit http://www.molecularassemblies.com.

Share article on social media or email:

SIU SDM Students Achieve 100% Pass Rate on Integrated National Board Dental Exam


The SIU SDM Class of 2021 gathered on campus during their 2017 orientation program.

“SIU School of Dental Medicine students continue to excel with strong dedication to their academic advancement and a commitment to achieving clinical mastery.”

The Southern Illinois University School of Dental Medicine (SIU SDM) is celebrating students in the class of 2021 for achieving a 100% first-time pass rate on the new Integrated National Board Dental Exam (INBDE).

The integrated examination for dental licensure replaces the NBDE Part I and Part II, and covers the basic, behavioral and clinical sciences. According to the Joint Commission on National Dental Examinations, the new exam combines content from several disciplines, requiring test takers to “integrate their knowledge of science with the clinical know-how involved in the safe practice of dentistry.”

“SIU School of Dental Medicine students continue to excel with strong dedication to their academic advancement and a commitment to achieving clinical mastery,” said SIU SDM Dean Bruce Rotter, DMD. “We are incredibly proud of this noteworthy accomplishment.”

The class of 2021 has endured the particular challenge of the COVID-19 pandemic affecting both their third and fourth year of dental clinical education.

“Despite the additional restrictions placed on them amid the pandemic, these students worked effectively to be productive and manage their patients and work toward fulfilling their graduation requirements,” said SIU SDM Associate Dean for Academic Affairs Saulius Drukteinis, DMD. “We also owe great thanks to SIU School of Dental Medicine faculty and staff for working so hard under the circumstances to help continue to deliver our highest standard of education.”

The SIU School of Dental Medicine students manage approximately 35,000 patient visits each year at its patient clinics in Alton and East St. Louis. In addition, students offer oral health treatment, screenings and education to more than 10,000 people annually through a wide variety of off-campus community outreach events. These opportunities provide students the training they need to graduate and become highly skilled dentists. The School of Dental Medicine is a vital oral health care provider for residents of southern and central Illinois, and the St. Louis metropolitan region.

Share article on social media or email:

Clinical Utility of GBinsight Comprehensive Genetic Testing Showcased at the 2020 National Lipid Association’s Scientific Sessions


nla, national lipid association, next-generation DNA sequencing, panels, next-gen, genetic testing, genetic analysis, cardiometabolic disease, polygenic risk scores, monogenic variants, NGS for researchers, bioinformatic pipeline, pathway-based, biologica

“GBinsight reflects the biological complexity of humans and, through comprehensive genetic testing and analysis, facilitates precise diagnosis and targeted treatment and prevention,” said Dr. Mendel Roth, Senior Scientist at GBinsight.

Genetics was a major theme of the National Lipid Association’s (NLA) Scientific Sessions, December 2020. Genetic testing for lipid disorders, polygenic risk scores for atherosclerotic cardiovascular disease (ASCVD) and the implications of genetics on clinical care, medical ethics and identifying individuals at high risk and preventive strategies were among the headlining topics. The clinical utility of GBinsight comprehensive genetic testing and analysis was highlighted by several leading physicians and scientists throughout the sessions.

Dr. Christie M. Ballantyne, Professor of Medicine and Genetics at Baylor College of Medicine, started off his presentation reflecting on the current state of clinical cardiovascular genetics, noting how “wonderful it is to see where we are now and what the impact of genetics will be on how we practice preventive cardiology.” Dr. Ballantyne then reinforced the statements of a previous presenter and another client of GBinsight, Dr. Zahid Ahmed, Assistant Professor of Medicine at the University of Texas, Southwestern, highlighting the clinical benefits of genetic testing for dyslipidemias and ASCVD patients including how definitive diagnoses increase the likelihood of payer coverage and provide more accurate risk stratification, enhance cascade screening that may prompt initiation of therapies at an earlier age, and allow for more precise medication regimens.

Drs. Christie Ballantyne and Zahid Ahmed, both GBinsight collaborators, emphasized that there is a 50% chance of passing on heterozygous familial hypercholesterolemia (FH) to one’s children. Genetic testing is the preferred method for screening young family members of adults with FH. The earlier a person is diagnosed, the sooner he or she can begin lifestyle and drug therapies that reduce risk of ASCVD.

The clinical applications of GBinsight were demonstrated by several presentations and posters from Baylor College of Medicine, UT Southwestern, and the University of Pennsylvania. Case studies of patients referred for severe hypertriglyceridemia, pancreatitis, and type 2 diabetes were showcased. GBinsight’s Comprehensive Dyslipidemia Panel identified pathogenic genetic variants causal for familial partial lipodystrophy (FPLD) in these patients and allowed physicians to identify precise diagnoses and offer precise therapies. GBinsight analyzes the multitude of pathways that cause severe hypertriglyceridemia beyond LPL deficiency.

“GBinsight recognizes the biological complexity and heterogeneity of humans and, through comprehensive genetic analysis, facilitates precise diagnosis. GBinsight comprehensively analyzes the genetics of the multitude of pathways that can cause dyslipidemia and ASCVD in a single assay,” said Dr. Mendel Roth, Senior Scientist at GBinsight.

GBinsight differentiates itself from other genetic testing services in several important ways: 1) Since ASCVD risk is ultimately determined by additive risk factors, GBinsight analyzes broad risk categories within a single comprehensive assay. This includes hypercholesterolemia, hypertriglyceridemia, reverse cholesterol transport defects, high Lp(a), homocysteinemia, familial obesity and familial diabetes. The analysis includes copy number variations that are a common cause of dyslipidemias. 2) Analyzes both rare, large-effect sized, monogenic variants largely in coding and splicing regions of genes as well as common, small-to-moderate-effect sized variants that contribute to polygenic risk in a single assay. 3) This assay includes full coverage of the APOE gene that is an underappreciated genetic cause of dyslipidemias and ASCVD. The APOE gene presents a technical challenge in getting quality sequencing results. 4) Analyzes both single nucleotide polymorphisms (SNP) known to increase and decrease Lp(a) levels as well as directly quantifies the variable Kringle-IV region. 5) Analyzes pharmacogenomics including the multiple genetic causes of statin intolerance.

“GBinsight is the only next-generation sequencing (NGS) test that can directly quantify the variable region within the LPA gene which is the single greatest cause of high Lp(a),” said Dr. Roth. “GBinsight employs a machine-learning algorithm that assesses the comprehensive genetic basis of high Lp(a).”

GBinsight’s scientific team has collaborated with key clinical opinion leaders to explore and validate the clinical utility of comprehensive genetic analysis for dyslipidemia and ASCVD. For example, using monogenic and polygenic analysis, up to 80% of patients referred to GBinsight for FH and other dyslipidemias was correctly identified. Of those with high Lp(a), validation results showed an overall accuracy of 84% with a sensitivity of 82% and specificity of 87%. Including the direct quantitation of the variable polymorphism increased the accuracy call by 23 percentage points. These results were formulated in partnerships with Drs. Christie M. Ballantyne, Michael Davidson at University of Chicago, Patrick Moriarty at University of Kansas, and Sotirios Tsimikas of University of California, San Diego and presented at the NLA Scientific Sessions.

GBinsight NGS services are performed at a CLIA-certified and medically licensed genetic testing laboratory using Illumina’s HiSeq platform.

GBinsight’s Test Catalog includes the following:

  • Dyslipidemia Comprehensive Panel
  • Familial Hypercholesterolemia Panel
  • Familial Hypertriglyceridemia Panel
  • Coronary Heart Disease Comprehensive Panel
  • Type 2 Diabetes Comprehensive Panel
  • Diabetes MODY Panel
  • Obesity Comprehensive Panel
  • Non-Syndromic Monogenic Obesity Panel
  • Alzheimer’s Disease Comprehensive Panel

Because genetic risk for most common metabolic diseases can be mitigated by dietary and lifestyle factors, in addition to GBinsight comprehensive genetic analysis, GB HealthWatch also developed the HealthWatch 360 mobile app for delivering dietary and lifestyle interventions to the general population. The app works in conjunction with the HealthWatch 360 Research Portal, which allows researchers to manage and analyze the diet, exercise and health data collected with the mobile app. Integration of GBinsight genetics panels with the research portal advantageously enables researchers to study gene-gene and gene-lifestyle interactions in observational and interventional cohort trials. With this system, prevention and medical intervention strategies, and especially dietary interventions, for complex diseases can be experimented with, validated and refined. Given the epidemic of diet-induced chronic diseases in the United States and worldwide, it is imperative that we focus our efforts on precision nutrition as a key preventive strategy for improving the health of our future.

GBinsight was developed by GB HealthWatch in partnership with the Otogenetics Corporation, a CLIA-certified and licensed medically licensed genetic testing company.

About GB HealthWatch

GB HealthWatch is a nutritional genomics company. We develop state-of-the-art technologies to facilitate research on the molecular mechanisms, clinical efficacy and cost-effectiveness of translating genetic insights into personalized prevention and treatment strategies for complex diseases. GB HealthWatch offers the following tools:

About Otogenetics Corporation

Otogenetics Corporation is a CLIA-certified and licensed medical genetic testing company specializing in next generation sequencing services. Otogenetics offers high quality services for genome, exome, and RNA-seq for government and academic institutions, biotechnology and pharmaceutical companies, as well as medical doctors and clinics. Additional services and products provided by Otogenetics Corporation can be found at: http://www.otogenetics.com

Share article on social media or email:

2021 iaedp™ Symposium on Eating Disorders Treatment Announces Presidents Council Support


“Through support of the Presidents Council, iaedp™ provides the appropriate training and competencies for professionals to function in all aspects of eating disorders treatment,” said Bonnie Harken, Managing Director of the iaedp™ Foundation.

The International Association of Eating Disorders Professionals (iaedp™) announce today key support for the 2021 iaedp™ Symposium from its Presidents Council, a collective group representing the leading eating disorders treatment centers from across the U.S. For 36 consecutive years, Presidents Council members have been key sponsors of the annual iaedp™ Symposium.

As partners of iaedp™, the Presidents Council demonstrates its dedication to the field of eating disorders treatment through financial support of iaedp™ and the organization’s mission of serving the professional eating disorders community through education, certification and member support.

“Through support of the Presidents Council, iaedp™ provides the appropriate training and competencies for professionals to function in all aspects of eating disorders treatment,” said Bonnie Harken, Managing Director of the iaedp™ Foundation.

Scheduled to premiere March 18 – 21, 2021 in a virtual format, the upcoming 2021 iaedp™ Symposium features keynote speakers, workshops and presentations, pre-certification courses. Offered to both national and international eating disorders treatment professionals, the iaedp™ Symposium is dedicated to meeting the needs of professionals in the treatment of eating disorders. Early registration is open through February 12, 2021, offering significant savings to participants.

The generosity of the 15 Presidents Council member organizations contributes to the iaedp™ Foundation’s ongoing educational opportunities specific to the treatment of eating disorders and provide these to healthcare professionals who treat eating disorders. The iaedp™ Foundation’s Board of Directors also recognizes the Presidents Council’s commitment to research in order to produce the most up-to-date and innovative education techniques available to the medical community.

Member organizations of the iaedp™ Presidents Council include:

  • Alsana
  • Center for Change
  • Center for Discovery
  • Eating Recovery Center
  • Laureate Eating Disorders Program
  • The Meadows Ranch
  • The Renfrew Center
  • Rogers Behavioral Health
  • Rosewood Centers for Eating Disorders
  • Selah House
  • SunCloud Health
  • Timberline Knolls
  • Veritas Collaborative
  • Walden Behavioral Care
  • Willow Place

About the iaedp™ Foundation: Since 1985, the International Association of Eating Disorders Professionals has provided education and training standards to an international and multidisciplinary group of various healthcare treatment providers and helping professions.

MemberSHARE.iaedp.com is an iaedp™ business journal and online member resource to learn about noteworthy member achievements, continuing education webinars, U.S. and International Chapter activity and events; for more information, visit MemberSHARE. More information about all aspects iaedp™ and its 2021 Symposium can be found at iaedp.com.

Share article on social media or email:

The American Mobile & Teledentistry Alliance adds Dr. Bill Jackson from Teledentix and Virtual Dental Care to its Corporate Advisory Board


We’re very excited to have Dr. Jackson and Teledentix contribute their wealth of telehealth technology expertise.

Virtual Dental Care (VDC), the company behind the industry-leading teledentistry software, Teledentix, has recently joined the corporate advisory board of the American Mobile and Teledentistry Alliance (AMTA) to help share insights and contribute to the continued growth and adoption of mobile and teledentistry delivery.

Dr. Bill Jackson, VDC Co-Founder and COO, will represent the company on the advisory board and work closely with the AMTA members and leadership to provide guidance around the use of technology in this rapidly changing sector.

Mobile and teledentistry-enabled expansion in the dental space is projected to help bridge the gap in oral care and ultimately contribute to the tighter integration of medical and dental. Dr. Jackson’s dental and telehealth technology expertise will help the AMTA identify and advocate for innovative ways of communicating with and treating patients.

According to studies conducted by McKinsey & Co., telehealth services in the United States are projected to grow by 830% in 2021 but there are still significant barriers to be addressed and overcome before that growth can be fully realized.

Dr. Jackson and the team at VDC are working to address those barriers particularly when it comes to technology and the value it brings to both patients and providers.

“Organizations like the AMTA are working to help educate the industry and shape the way we think of teledentistry and its impact on the overall telehealth space and we believe our company’s vision, and product, Teledentix, are going to play a crucial role in this evolution of healthcare,” noted Dr. Jackson.

“The AMTA seeks to foster a community of critical thought and discussion to support common initiatives among all stakeholders in the industry and we’re very excited to have Dr. Jackson and Teledentix contribute their wealth of telehealth technology expertise,” added Melissa Turner, AMTA Co-Founder.

“The AMTA is a true alliance in that we partner with stakeholders, as well as dental professionals from across the world, to advance the care delivery model and guide the industry into the future that we know is coming for healthcare,” remarked Sonya Dunbar, AMTA Co-Founder.

About Virtual Dental Care and Teledentix

Teledentix, by Virtual Dental Care, is the most comprehensive teledentistry software on the market. Teledentix was built with a vision to help teledentistry become a widely used industry norm, expanding dentistry and a dentist’s role beyond the walls of a dental office – even into the broader healthcare system. For more information about Teledentix, visit https://get.teledentix.com/.

About the American Mobile & Teledentistry Alliance

The AMTA consists of individual healthcare professionals, medical and dental practices, corporate partners, and other stakeholders whose interests are to help facilitate the advancement of mobile & teledentistry. Organizational partners are those who provide clinical or supportive services, affiliated site partners, product and service companies, health departments, coalitions, and others. Learn more at https://www.amda.net/.

Share article on social media or email:

International Consortium Awarded Eurostars Grant for the Development of First-in-class Treatment of Metastatic Cancer


News Image

ONA Therapeutics, Absolute Antibody and RIC – three leading European companies in the biotech landscape – have been awarded a Eurostars grant for a two-year project that will develop a proprietary biological drug with a unique mode of action for the treatment of various types of metastatic cancers. Taking the lives of more than 9 million people globally each year, metastatic cancers are often unresponsive to existing cancer treatments, leaving a large unmet need. In order to tackle this important health problem, the newly established consortium – named LIPOLOGIC – will combine industry know-how in complementary areas of drug development: from target discovery, across molecule formatting and manufacturing, to lead selection and characterization.

ONA Therapeutics, a Spanish biotech company specialized in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism, will take the lead in the LIPOLOGIC program. “Our research demonstrates that the survival of metastatic cells is linked to the intake of certain saturated fats and if we block the capacity for intake of these fats, we significantly reduce the cell’s metastatic potential. We are excited to partner with Absolute Antibody and RIC to develop novel revolutionary therapies that target this mechanism of action and with the potential to treat multiple types of metastatic cancer” said ONA co-founder and CEO Valerie Vanhooren.

Absolute Antibody, experts in recombinant antibody technology, will engineer the biologic into an optimized format and then recombinantly produce and purify the molecule for preclinical analysis. According to Ian Wilkinson, Chief Scientific Officer, “Our contribution to the team will result in a reproducible, defined biologic to progress to the IND stage and clinical trials. We are very excited about the potential of this unique mode of action.”

RIC, expert in biopharma analytics, will apply its comprehensive knowledge and in-house platforms to provide the CMC data necessary for evaluating the project’s candidate molecules and selecting the best lead: identifying physicochemical liabilities, better understanding target binding through epitope mapping and evaluating overall pharmacokinetics. “The complex nature of biological products makes the development of innovative therapies like these truly challenging. We are proud to bring our analytical skill set to the table and help make this new type of treatment a reality” said Koen Sandra, CEO at RIC.

The LIPOLOGIC consortium has just kicked off its pre-clinical development against a variety of tumor types and plans to move its lead candidate into first clinical studies in patients with metastatic cancer in the upcoming years. The initiative is funded by the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and innovation program.

About ONA Therapeutics, SL

ONA Therapeutics, with headquarters in the Barcelona Science Park (PCB), Barcelona, Spain, is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and the IRB Institute for Research in Biomedicine. Learn more at ONA-therapeutics.com.

About Absolute Antibody, Ltd.

Absolute Antibody is a rapidly growing company with a vision to make recombinant antibody technology accessible to all. We offer antibody sequencing, engineering and recombinant production as custom services, as well as a unique catalog of recombinant antibodies, engineered into new and useful formats. Learn more at AbsoluteAntibody.com.

About RIC, BV

RIC is a privately-owned European center of excellence in the field of analytical solutions with headquarters in Kortrijk, Belgium. For more than 35 years RIC has been supporting customers worldwide in various industries with scientific know-how and technical expertise. Under its brand name “RIC biologics” it provides all-round analytical solutions to pharma and biotech companies working on biological products and chemical entities. Learn more at RIC-biologics.com.

Contact:

Mercè de Frias, Chief Operating Officer at ONA Therapeutics

info@ona-therapeutics.com

###

Share article on social media or email:

Heart to Heart Hospice Foundation Endows Five Separate Nursing Scholarships Totaling $125,000


News Image

“The greatest impact we have is through the ripple effect of education.”

As part of its commitment to educating healthcare professionals and serving communities, the Heart to Heart Hospice Foundation has made endowments totaling $125,000 to the nursing programs of five colleges and universities located throughout Texas, Michigan, and Indiana.

The established “Heart to Heart Hospice Foundation Endowed Nursing Scholarship” will be awarded to nursing students based upon character, academic ability, and financial need at the following schools: Tyler Junior College in Tyler, Texas; the University of Mary Hardin-Baylor in Belton, Texas; Lansing Community College in Lansing, Michigan; the University of Saint Francis in Fort Wayne, Indiana; and the University of Southern Indiana in Evansville, Indiana.

“Heart to Heart Hospice Foundation is thrilled to partner with these outstanding schools,” said Michelle Newton, Chief Operations Officer of Heart to Heart Hospice. “Together we are preparing our future nurses to provide professional, patient-centered, and often heroic care to those in need, often the most vulnerable among us.

“For many, nursing is a calling,” she added, “and this is especially true of those who serve in hospice care as they learn to treat the whole person and help their families through the end-of-life journey. Nurses are critical, on so many levels, to meeting the increasing needs of our healthcare system and our society.”

The Heart to Heart Hospice Foundation endowment is made available through the foundation’s Education and Scholarship program – one of its unique programs designed to reach those in the community by providing greater care, greater education, and a commitment to celebrate life.

“We believe that the greatest impact we have is through the ripple effect of education,” said Kelly Mitchell, CEO and Founder of Heart to Heart Hospice and President of Heart to Heart Hospice Foundation. “By training compassionate caregivers today, we are creating a brighter tomorrow. We are pleased to be a part of the respected nursing programs at these fine institutions.”

About Heart to Heart Hospice Foundation

Funded primarily through generous donations from families and friends of Heart to Heart Hospice patients, the Heart to Heart Hospice Foundation is a 501(c) (3) non-profit public charity that provides financial support for patients nearing end-of-life, their families, and the greater community through various charitable programs. Each program includes financial support for critical unmet needs, as well as much-needed education for the under-utilized and often misinterpreted field of hospice and palliative care. Learn more about the Heart to Heart Hospice Foundation.

About Heart to Heart Hospice

Heart to Heart Hospice, founded in 2003, is one of the largest private providers of hospice care in the United States. Headquartered in the Dallas-Fort Worth Metroplex, Heart to Heart provides a broad range of hospice services to patients with life-limiting illnesses across 43 locations in Texas, Michigan and Indiana. At Heart to Heart, we understand both the physical and emotional challenges for our patients and their loved ones and our care team is committed to providing them with what they need most: comfort, support and dignity. Learn more about Heart to Heart Hospice.

Share article on social media or email: